Fifth Third Bancorp
ENTA icon

Fifth Third Bancorp’s Enanta Pharmaceuticals ENTA Stock Holding History

Fifth Third Bancorp’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.63K Buy
+367
New +$4.92K ﹤0.01% 3886
2025
Q3 		– Sell
-111
Closed -$839 – 2696
2025
Q2 		$839 Buy
+111
New +$668 ﹤0.01% 2447
2023
Q4 		– Sell
-358
Closed -$4K – 2537
2023
Q3 		$4K Buy
358
+339
+1,784% +$5.46K ﹤0.01% 2231
2023
Q2 		$407 Sell
19
-25
-57% -$737 ﹤0.01% 2565
2023
Q1 		$1.78K Hold
44
– – ﹤0.01% 2567
2022
Q4 		$2.05K Hold
44
– – ﹤0.01% 2427
2022
Q3 		$2K Hold
44
– – ﹤0.01% 2420
2022
Q2 		$2K Sell
44
-18
-29% -$977 ﹤0.01% 2428
2022
Q1 		$4K Sell
62
-2
-3% -$130 ﹤0.01% 2359
2021
Q4 		$5K Buy
64
+45
+237% +$3.53K ﹤0.01% 2321
2021
Q3 		$1K Buy
+19
New +$939 ﹤0.01% 2560
2019
Q4 		– Sell
-28
Closed -$2K – 2237
2019
Q3 		$2K Buy
+28
New +$2.08K ﹤0.01% 2047
2016
Q1 		– Sell
-37
Closed -$1K – 2408
2015
Q4 		$1K Sell
37
-21
-36% -$684 ﹤0.01% 2594
2015
Q3 		$2K Buy
+58
New +$2.49K ﹤0.01% 2592

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fifth Third Bancorp's ENTA Position: Q1 2026 in Review

Fifth Third Bancorp opened a new position in Enanta Pharmaceuticals (ENTA) in Q1 2026: 367 shares worth $4.63K. The stake represents ﹤0.01% of the portfolio and ranks #3886 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in ENTA as recently as Q2 2025.

Fifth Third Bancorp first reported a position in ENTA in Q3 2015 and has held it in 14 quarters since. The position peaked at $5K in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Fifth Third Bancorp held 367 shares of Enanta Pharmaceuticals worth $4.63K as of Q1 2026.
  • Enanta Pharmaceuticals was a new Fifth Third Bancorp position in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #3886 holding.
  • Fifth Third Bancorp first reported a position in Enanta Pharmaceuticals in Q3 2015 and has held it in 14 quarters since.
  • Fifth Third Bancorp's Enanta Pharmaceuticals position peaked at $5K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.